Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oramed Pharmaceuticals (ORMP) Enterprise Value (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Enterprise Value for 3 consecutive years, with -$100.5 million as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Enterprise Value rose 20.59% year-over-year to -$100.5 million, compared with a TTM value of -$100.5 million through Sep 2024, up 20.59%, and an annual FY2023 reading of -$67.7 million, down 50.89% over the prior year.
  • Enterprise Value was -$100.5 million for Q3 2024 at Oramed Pharmaceuticals, down from -$87.4 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$8.0 million in Q2 2023 and bottomed at -$126.5 million in Q3 2023.
  • Average Enterprise Value over 3 years is -$61.1 million, with a median of -$44.9 million recorded in 2022.
  • The sharpest move saw Enterprise Value soared 78.5% in 2023, then plummeted 994.12% in 2024.
  • Year by year, Enterprise Value stood at -$44.9 million in 2022, then crashed by 50.89% to -$67.7 million in 2023, then tumbled by 48.43% to -$100.5 million in 2024.
  • Business Quant data shows Enterprise Value for ORMP at -$100.5 million in Q3 2024, -$87.4 million in Q2 2024, and -$99.8 million in Q1 2024.